<DOC>
	<DOC>NCT01339559</DOC>
	<brief_summary>This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).</brief_summary>
	<brief_title>Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy</brief_title>
	<detailed_description>The primary objective is to evaluate the long term safety and tolerability of BRV at individualized doses up to a maximum of 200 mg/day in epilepsy subjects.</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subject completed the Treatment Period of N01358 or the evaluation period of N01258 Male/female subject from 16 years or older. Subject under 18 years may only be included where legally permitted and ethically accepted Subject for whom the Investigator believes a reasonable benefit from the long term administration of BRV may be expected Female subject without childbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible Subject has developed hypersensitivity to any components of the investigational medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core studies Severe medical, neurological, or psychiatric disorders, or laboratory values which may have an impact on the safety of the subject Poor compliance with the visit schedule or medication intake in the previous BRV study Planned participation in any other clinical study of another investigational drug or device during this study Pregnant or lactating woman Any medical condition which, in the Investigator's opinion, warrants exclusion Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Adjunctive treatment</keyword>
</DOC>